[ad_1]
A memorable phase of Cold War relief also appears to occur in the war against coronavirus vaccines, with the reconciliation of Russian and British vaccines.
The developer of Russia’s Sputnik V coronavirus vaccine, the state-owned Gamaleja Research Institute, is launching a joint experiment with British-Swedish pharmaceutical company AstraZeneca mult to find out if the latter, a less colorful vaccine called AZD1222 , it is most effective when used together with the Russian drug. .
The Russian developer had already started the experiment two weeks ago, in which he found a partner in AstraZeneca. The latter confirmed that investigations will be launched soon, how much time will be spent on this, was not disclosed. The two formulations are based on similar bases, which may allow their possible combination. The tests will be performed on people over 18 years of age.
AstraZeneca was the first pharmaceutical company to publish research results on its coronavirus vaccination. Its preparation was developed in collaboration with the University of Oxford. According to a report by The Lancet, the vaccine is 70 percent effective on average, but compared to its better-performing competitors, which require additional cryopreservation, this vaccine is easy to transport and can be stored in a normal refrigerator.
[ad_2]
